JP2014508128A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014508128A5 JP2014508128A5 JP2013546401A JP2013546401A JP2014508128A5 JP 2014508128 A5 JP2014508128 A5 JP 2014508128A5 JP 2013546401 A JP2013546401 A JP 2013546401A JP 2013546401 A JP2013546401 A JP 2013546401A JP 2014508128 A5 JP2014508128 A5 JP 2014508128A5
- Authority
- JP
- Japan
- Prior art keywords
- bicyclo
- octan
- carboxamide
- methyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 alkyl carbamate Chemical compound 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 29
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 208000015114 central nervous system disease Diseases 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims description 4
- 125000004306 triazinyl group Chemical group 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 230000001149 cognitive effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 230000000626 neurodegenerative effect Effects 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 208000020016 psychiatric disease Diseases 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims 7
- 208000020401 Depressive disease Diseases 0.000 claims 5
- 208000024714 major depressive disease Diseases 0.000 claims 4
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims 4
- QWEWLLNSJDTOKH-UHFFFAOYSA-N 1,3-thiazole-2-carboxamide Chemical compound NC(=O)C1=NC=CS1 QWEWLLNSJDTOKH-UHFFFAOYSA-N 0.000 claims 3
- PABVQLMXDGVYBS-UHFFFAOYSA-N 6-methylpyrazine-2-carboxamide Chemical compound CC1=CN=CC(C(N)=O)=N1 PABVQLMXDGVYBS-UHFFFAOYSA-N 0.000 claims 3
- 230000036506 anxiety Effects 0.000 claims 3
- JVNOQZOWRVXECJ-VQTJNVASSA-N 5-fluoro-n-[(1r,5s)-5-(pyridine-2-carbonylamino)-1-bicyclo[3.2.1]octanyl]pyridine-2-carboxamide Chemical compound N1=CC(F)=CC=C1C(=O)N[C@@]1(CCC2)C[C@@]2(NC(=O)C=2N=CC=CC=2)CC1 JVNOQZOWRVXECJ-VQTJNVASSA-N 0.000 claims 2
- BCCUXBGEPLKSEX-UHFFFAOYSA-N 5-methylpyridine-3-carboxamide Chemical compound CC1=CN=CC(C(N)=O)=C1 BCCUXBGEPLKSEX-UHFFFAOYSA-N 0.000 claims 2
- DESCPWKNFVHGHO-VQTJNVASSA-N 6-fluoro-n-[(1r,5s)-5-(pyridine-2-carbonylamino)-1-bicyclo[3.2.1]octanyl]pyridine-2-carboxamide Chemical compound FC1=CC=CC(C(=O)N[C@@]23C[C@@](CC2)(CCC3)NC(=O)C=2N=CC=CC=2)=N1 DESCPWKNFVHGHO-VQTJNVASSA-N 0.000 claims 2
- OCVKYJFCWLTEPM-RTWAWAEBSA-N 6-methyl-n-[(1r,5s)-1-(pyridine-2-carbonylamino)-5-bicyclo[3.2.1]octanyl]pyridine-2-carboxamide Chemical compound CC1=CC=CC(C(=O)N[C@]23C[C@](CC2)(CCC3)NC(=O)C=2N=CC=CC=2)=N1 OCVKYJFCWLTEPM-RTWAWAEBSA-N 0.000 claims 2
- OCVKYJFCWLTEPM-LEWJYISDSA-N 6-methyl-n-[(1s,5r)-1-(pyridine-2-carbonylamino)-5-bicyclo[3.2.1]octanyl]pyridine-2-carboxamide Chemical compound CC1=CC=CC(C(=O)N[C@@]23C[C@@](CC2)(CCC3)NC(=O)C=2N=CC=CC=2)=N1 OCVKYJFCWLTEPM-LEWJYISDSA-N 0.000 claims 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 2
- 201000003104 endogenous depression Diseases 0.000 claims 2
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 2
- HKSQZEGSMBFHGC-UHFFFAOYSA-N pyrimidine-4-carboxamide Chemical compound NC(=O)C1=CC=NC=N1 HKSQZEGSMBFHGC-UHFFFAOYSA-N 0.000 claims 2
- XHWVYZXQFZPTLE-VQTJNVASSA-N 2-methyl-n-[(1r,5s)-5-(pyridine-2-carbonylamino)-1-bicyclo[3.2.1]octanyl]pyrimidine-4-carboxamide Chemical compound CC1=NC=CC(C(=O)N[C@@]23C[C@@](CC2)(CCC3)NC(=O)C=2N=CC=CC=2)=N1 XHWVYZXQFZPTLE-VQTJNVASSA-N 0.000 claims 1
- OZSDTKZLTREFCH-UHFFFAOYSA-N 3-fluoro-6-methylpyridine-2-carboxylic acid Chemical compound CC1=CC=C(F)C(C(O)=O)=N1 OZSDTKZLTREFCH-UHFFFAOYSA-N 0.000 claims 1
- DDPNELLXOVSMGM-RBUKOAKNSA-N 4-methyl-n-[(1s,5r)-1-(pyridine-2-carbonylamino)-5-bicyclo[3.2.1]octanyl]-1,3-thiazole-2-carboxamide Chemical compound CC1=CSC(C(=O)N[C@@]23C[C@@](CC2)(CCC3)NC(=O)C=2N=CC=CC=2)=N1 DDPNELLXOVSMGM-RBUKOAKNSA-N 0.000 claims 1
- DPOOKUAQJYZPIH-UHFFFAOYSA-N 5-methyl-n-[1-(pyrimidine-4-carbonylamino)-5-bicyclo[3.2.1]octanyl]pyrazine-2-carboxamide Chemical compound C1=NC(C)=CN=C1C(=O)NC1(CCC2)CC2(NC(=O)C=2N=CN=CC=2)CC1 DPOOKUAQJYZPIH-UHFFFAOYSA-N 0.000 claims 1
- OYBQCUZBVHFPBU-UHFFFAOYSA-N 5-methylpyrazine-2-carboxamide Chemical compound CC1=CN=C(C(N)=O)C=N1 OYBQCUZBVHFPBU-UHFFFAOYSA-N 0.000 claims 1
- CWFPGAIJKMNVBI-UXHICEINSA-N 6-methyl-n-[(1r,5s)-1-(pyridine-2-carbonylamino)-5-bicyclo[3.2.1]octanyl]pyrazine-2-carboxamide Chemical compound CC1=CN=CC(C(=O)N[C@]23C[C@](CC2)(CCC3)NC(=O)C=2N=CC=CC=2)=N1 CWFPGAIJKMNVBI-UXHICEINSA-N 0.000 claims 1
- CWFPGAIJKMNVBI-VQTJNVASSA-N 6-methyl-n-[(1s,5r)-1-(pyridine-2-carbonylamino)-5-bicyclo[3.2.1]octanyl]pyrazine-2-carboxamide Chemical compound CC1=CN=CC(C(=O)N[C@@]23C[C@@](CC2)(CCC3)NC(=O)C=2N=CC=CC=2)=N1 CWFPGAIJKMNVBI-VQTJNVASSA-N 0.000 claims 1
- CWFPGAIJKMNVBI-UHFFFAOYSA-N 6-methyl-n-[1-(pyridine-2-carbonylamino)-5-bicyclo[3.2.1]octanyl]pyrazine-2-carboxamide Chemical compound CC1=CN=CC(C(=O)NC23CC(CC2)(CCC3)NC(=O)C=2N=CC=CC=2)=N1 CWFPGAIJKMNVBI-UHFFFAOYSA-N 0.000 claims 1
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000020446 Cardiac disease Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 235000002597 Solanum melongena Nutrition 0.000 claims 1
- 244000061458 Solanum melongena Species 0.000 claims 1
- 230000006389 acute stress response Effects 0.000 claims 1
- 230000006978 adaptation Effects 0.000 claims 1
- 208000012826 adjustment disease Diseases 0.000 claims 1
- 208000029650 alcohol withdrawal Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 208000025748 atypical depressive disease Diseases 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000025307 bipolar depression Diseases 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- BCEYKJNPCWQUTL-UXHICEINSA-N n-[(1r,5s)-5-[(6-methylpyridine-2-carbonyl)amino]-1-bicyclo[3.2.1]octanyl]pyrimidine-4-carboxamide Chemical compound CC1=CC=CC(C(=O)N[C@]23C[C@](CC2)(CCC3)NC(=O)C=2N=CN=CC=2)=N1 BCEYKJNPCWQUTL-UXHICEINSA-N 0.000 claims 1
- XURKWFWIYAQJGJ-RBUKOAKNSA-N n-[(1s,5r)-1-[(6-methylpyridine-2-carbonyl)amino]-5-bicyclo[3.2.1]octanyl]-1,3-thiazole-2-carboxamide Chemical compound CC1=CC=CC(C(=O)N[C@]23C[C@](CC2)(CCC3)NC(=O)C=2SC=CN=2)=N1 XURKWFWIYAQJGJ-RBUKOAKNSA-N 0.000 claims 1
- BCEYKJNPCWQUTL-VQTJNVASSA-N n-[(1s,5r)-5-[(6-methylpyridine-2-carbonyl)amino]-1-bicyclo[3.2.1]octanyl]pyrimidine-4-carboxamide Chemical compound CC1=CC=CC(C(=O)N[C@@]23C[C@@](CC2)(CCC3)NC(=O)C=2N=CN=CC=2)=N1 BCEYKJNPCWQUTL-VQTJNVASSA-N 0.000 claims 1
- XIJIWQOWOWSHNN-UHFFFAOYSA-N n-[1-[(4-methylpyridine-2-carbonyl)amino]-5-bicyclo[3.2.1]octanyl]pyrazine-2-carboxamide Chemical compound CC1=CC=NC(C(=O)NC23CC(CC2)(CCC3)NC(=O)C=2N=CC=NC=2)=C1 XIJIWQOWOWSHNN-UHFFFAOYSA-N 0.000 claims 1
- RSWLKNNEKJMTPU-UHFFFAOYSA-N n-[1-[(5-fluoropyridine-2-carbonyl)amino]-5-bicyclo[3.2.1]octanyl]pyrazine-2-carboxamide Chemical compound N1=CC(F)=CC=C1C(=O)NC1(CCC2)CC2(NC(=O)C=2N=CC=NC=2)CC1 RSWLKNNEKJMTPU-UHFFFAOYSA-N 0.000 claims 1
- TVKHKQGELWUTQW-UHFFFAOYSA-N n-[1-[(6-methylpyridin-2-yl)carbamoyl]-5-bicyclo[3.2.1]octanyl]-1,3-thiazole-2-carboxamide Chemical compound CC1=CC=CC(NC(=O)C23CC(CC2)(CCC3)NC(=O)C=2SC=CN=2)=N1 TVKHKQGELWUTQW-UHFFFAOYSA-N 0.000 claims 1
- TYZGEGRPQHQHHB-UHFFFAOYSA-N n-[1-[(6-methylpyridin-2-yl)carbamoyl]-5-bicyclo[3.2.1]octanyl]pyrazine-2-carboxamide Chemical compound CC1=CC=CC(NC(=O)C23CC(CC2)(CCC3)NC(=O)C=2N=CC=NC=2)=N1 TYZGEGRPQHQHHB-UHFFFAOYSA-N 0.000 claims 1
- RIEHSFZHPBDKTM-UHFFFAOYSA-N n-[1-[(6-methylpyridin-2-yl)carbamoyl]-5-bicyclo[3.2.1]octanyl]pyridine-2-carboxamide Chemical compound CC1=CC=CC(NC(=O)C23CC(CC2)(CCC3)NC(=O)C=2N=CC=CC=2)=N1 RIEHSFZHPBDKTM-UHFFFAOYSA-N 0.000 claims 1
- XURKWFWIYAQJGJ-UHFFFAOYSA-N n-[1-[(6-methylpyridine-2-carbonyl)amino]-5-bicyclo[3.2.1]octanyl]-1,3-thiazole-2-carboxamide Chemical compound CC1=CC=CC(C(=O)NC23CC(CC2)(CCC3)NC(=O)C=2SC=CN=2)=N1 XURKWFWIYAQJGJ-UHFFFAOYSA-N 0.000 claims 1
- YMXWZZMWGKZYKO-UHFFFAOYSA-N n-[1-[(6-methylpyridine-2-carbonyl)amino]-5-bicyclo[3.2.1]octanyl]pyrazine-2-carboxamide Chemical compound CC1=CC=CC(C(=O)NC23CC(CC2)(CCC3)NC(=O)C=2N=CC=NC=2)=N1 YMXWZZMWGKZYKO-UHFFFAOYSA-N 0.000 claims 1
- AHXCIGWCCCYWLC-UHFFFAOYSA-N n-[1-[(6-methylpyridine-2-carbonyl)amino]-5-bicyclo[3.2.1]octanyl]pyrimidine-2-carboxamide Chemical compound CC1=CC=CC(C(=O)NC23CC(CC2)(CCC3)NC(=O)C=2N=CC=CN=2)=N1 AHXCIGWCCCYWLC-UHFFFAOYSA-N 0.000 claims 1
- YXHWFCJODPXPON-UHFFFAOYSA-N n-[5-[(3-fluoropyridine-2-carbonyl)amino]-1-bicyclo[3.2.1]octanyl]pyrazine-2-carboxamide Chemical compound FC1=CC=CN=C1C(=O)NC1(CCC2)CC2(NC(=O)C=2N=CC=NC=2)CC1 YXHWFCJODPXPON-UHFFFAOYSA-N 0.000 claims 1
- BCEYKJNPCWQUTL-UHFFFAOYSA-N n-[5-[(6-methylpyridine-2-carbonyl)amino]-1-bicyclo[3.2.1]octanyl]pyrimidine-4-carboxamide Chemical compound CC1=CC=CC(C(=O)NC23CC(CC2)(CCC3)NC(=O)C=2N=CN=CC=2)=N1 BCEYKJNPCWQUTL-UHFFFAOYSA-N 0.000 claims 1
- 208000015238 neurotic disease Diseases 0.000 claims 1
- 229960003966 nicotinamide Drugs 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 239000011570 nicotinamide Substances 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- FUXJMHXHGDAHPD-UHFFFAOYSA-N pyrimidine-2-carboxamide Chemical compound NC(=O)C1=NC=CC=N1 FUXJMHXHGDAHPD-UHFFFAOYSA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 0 *C(NC(CC1)(C2)CCCC12I*)O Chemical compound *C(NC(CC1)(C2)CCCC12I*)O 0.000 description 1
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061426379P | 2010-12-22 | 2010-12-22 | |
| US61/426,379 | 2010-12-22 | ||
| PCT/US2011/066690 WO2012088365A1 (en) | 2010-12-22 | 2011-12-22 | Bicyclo[3.2.1]octyl amide derivatives and uses of same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016041981A Division JP6087006B2 (ja) | 2010-12-22 | 2016-03-04 | ビシクロ［３．２．１］オクチルアミド誘導体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014508128A JP2014508128A (ja) | 2014-04-03 |
| JP2014508128A5 true JP2014508128A5 (enExample) | 2015-02-19 |
| JP5992436B2 JP5992436B2 (ja) | 2016-09-14 |
Family
ID=46314466
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013546401A Expired - Fee Related JP5992436B2 (ja) | 2010-12-22 | 2011-12-22 | ビシクロ［３．２．１］オクチルアミド誘導体およびその使用 |
| JP2016041981A Expired - Fee Related JP6087006B2 (ja) | 2010-12-22 | 2016-03-04 | ビシクロ［３．２．１］オクチルアミド誘導体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016041981A Expired - Fee Related JP6087006B2 (ja) | 2010-12-22 | 2016-03-04 | ビシクロ［３．２．１］オクチルアミド誘導体およびその使用 |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8921370B2 (enExample) |
| EP (2) | EP3263566A1 (enExample) |
| JP (2) | JP5992436B2 (enExample) |
| KR (1) | KR101840076B1 (enExample) |
| CN (2) | CN103369961B (enExample) |
| AP (1) | AP3758A (enExample) |
| AR (1) | AR084457A1 (enExample) |
| AU (2) | AU2011348188B2 (enExample) |
| BR (1) | BR112013015592A8 (enExample) |
| CA (1) | CA2821937A1 (enExample) |
| CO (1) | CO6741203A2 (enExample) |
| CR (1) | CR20130309A (enExample) |
| DO (1) | DOP2013000142A (enExample) |
| EA (1) | EA026362B1 (enExample) |
| EC (1) | ECSP13012788A (enExample) |
| GE (1) | GEP20156219B (enExample) |
| GT (1) | GT201300164A (enExample) |
| IL (1) | IL226981A (enExample) |
| MA (1) | MA34819B1 (enExample) |
| MX (2) | MX349132B (enExample) |
| MY (1) | MY169432A (enExample) |
| NZ (2) | NZ705710A (enExample) |
| PE (1) | PE20141529A1 (enExample) |
| PH (1) | PH12013501340A1 (enExample) |
| SG (1) | SG191317A1 (enExample) |
| TN (1) | TN2013000253A1 (enExample) |
| TW (1) | TWI538905B (enExample) |
| UA (1) | UA109802C2 (enExample) |
| WO (1) | WO2012088365A1 (enExample) |
| ZA (2) | ZA201304624B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012015097A (es) | 2010-07-02 | 2013-05-28 | Gilead Sciences Inc | Derivados de acido naft-2-ilacetico para tratar sida. |
| US9296758B2 (en) | 2010-07-02 | 2016-03-29 | Gilead Sciences, Inc. | 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds |
| AR084457A1 (es) * | 2010-12-22 | 2013-05-15 | Lundbeck & Co As H | Derivados de biciclo[3,2,1]octilamida |
| EP3181555B1 (en) | 2011-04-21 | 2018-11-28 | Gilead Sciences, Inc. | Benzothiazole compounds and their pharmaceutical use |
| CN103827104A (zh) * | 2011-09-16 | 2014-05-28 | H.隆德贝克有限公司 | 双碳环和三碳环乙炔基衍生物及其应用 |
| US9376392B2 (en) | 2012-01-04 | 2016-06-28 | Gilead Sciences, Inc. | 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS |
| WO2013103738A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | Napthalene acetic acid derivatives against hiv infection |
| MD20140063A2 (ro) | 2012-04-20 | 2014-12-31 | Gilead Sciences, Inc. | Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV |
| US11083725B2 (en) | 2014-10-24 | 2021-08-10 | St. Jude Children's Research Hospital | Coordinated metabolic reprogramming in response to productive viral infections |
| BR112017023764A2 (pt) * | 2015-05-05 | 2018-07-31 | Bayer Pharma AG | derivados de ciclohexano substituído por amido |
| WO2016205304A1 (en) * | 2015-06-16 | 2016-12-22 | Signal Pharmaceuticals, Llc | Methods of treatment using substituted diaminopyrimidyl compounds |
| TW201808903A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808914A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808888A (zh) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW202506629A (zh) * | 2016-05-05 | 2025-02-16 | 美商嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| CN110730777A (zh) * | 2017-06-07 | 2020-01-24 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为atf4通路抑制剂的化学化合物 |
| JP2020525513A (ja) * | 2017-07-03 | 2020-08-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 癌および他の疾患を治療するためのａｔｆ４阻害剤としてのｎ−（３−（２−（４−クロロフェノキシ）アセトアミドビシクロ［１．１．１］ペンタン−１−イル）−２−シクロブタン−１−カルボキサミド誘導体および関連化合物 |
| CR20200054A (es) | 2017-08-09 | 2020-03-21 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
| PT3676297T (pt) | 2017-09-01 | 2023-08-29 | Denali Therapeutics Inc | Compostos, composições e métodos |
| UY37956A (es) * | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| UY37957A (es) * | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| IL274367B2 (en) * | 2017-11-02 | 2023-10-01 | Calico Life Sciences Llc | Combined pressure pathway modulators |
| MX2020004557A (es) | 2017-11-02 | 2020-10-05 | Calico Life Sciences Llc | Moduladores de la vía de estrés integrada. |
| EP3768660A1 (en) * | 2018-03-23 | 2021-01-27 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| TWI832295B (zh) | 2018-10-11 | 2024-02-11 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| TWI877136B (zh) | 2019-02-13 | 2025-03-21 | 美商戴納立製藥公司 | 化合物、組合物及方法 |
| US12091392B2 (en) | 2019-02-13 | 2024-09-17 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| EP4049661A4 (en) * | 2019-10-21 | 2023-11-08 | SK Biopharmaceuticals Co., Ltd. | USE OF AN IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE COMPOUND TO PREVENT, RELIEF OR TREAT DEVELOPMENTAL DISABILITIES |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU743899B2 (en) | 1997-07-18 | 2002-02-07 | Georgetown University | Bicyclic metabotropic glutamate receptor ligands |
| PE20001236A1 (es) * | 1998-11-13 | 2000-11-10 | Lilly Co Eli | Moduladores del receptor de aminoacidos excitadores |
| AU778063C (en) | 1999-06-02 | 2005-12-15 | Astrazeneca Ab | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
| EP1214303A1 (en) * | 1999-08-31 | 2002-06-19 | Merck & Co., Inc. | Heterocyclic compounds and methods of use thereof |
| EP1230243B1 (en) * | 1999-11-12 | 2009-03-04 | Biogen Idec MA Inc. | Poycyloalkylpurines as adenosine receptor antagonists |
| SI1867644T1 (sl) | 2003-07-24 | 2009-10-31 | Euro Celtique Sa | Heteroaril-tetrahidropiperidilne spojine, koristne za zdravljenje ali preprečevanje bolečine |
| DK2310356T3 (da) * | 2008-07-25 | 2013-10-21 | Lundbeck & Co As H | Adamantyl-diamid-derivater og anvendelser deraf |
| AR084457A1 (es) * | 2010-12-22 | 2013-05-15 | Lundbeck & Co As H | Derivados de biciclo[3,2,1]octilamida |
-
2011
- 2011-12-21 AR ARP110104844A patent/AR084457A1/es unknown
- 2011-12-21 TW TW100147680A patent/TWI538905B/zh not_active IP Right Cessation
- 2011-12-22 CA CA2821937A patent/CA2821937A1/en not_active Abandoned
- 2011-12-22 UA UAA201308888A patent/UA109802C2/uk unknown
- 2011-12-22 BR BR112013015592A patent/BR112013015592A8/pt not_active IP Right Cessation
- 2011-12-22 KR KR1020137016284A patent/KR101840076B1/ko not_active Expired - Fee Related
- 2011-12-22 NZ NZ705710A patent/NZ705710A/en not_active IP Right Cessation
- 2011-12-22 CN CN201180067923.3A patent/CN103369961B/zh not_active Expired - Fee Related
- 2011-12-22 EP EP17178046.3A patent/EP3263566A1/en not_active Withdrawn
- 2011-12-22 JP JP2013546401A patent/JP5992436B2/ja not_active Expired - Fee Related
- 2011-12-22 WO PCT/US2011/066690 patent/WO2012088365A1/en not_active Ceased
- 2011-12-22 GE GEAP201113166A patent/GEP20156219B/en unknown
- 2011-12-22 SG SG2013048558A patent/SG191317A1/en unknown
- 2011-12-22 EA EA201390908A patent/EA026362B1/ru not_active IP Right Cessation
- 2011-12-22 PE PE2013001463A patent/PE20141529A1/es not_active Application Discontinuation
- 2011-12-22 AU AU2011348188A patent/AU2011348188B2/en not_active Ceased
- 2011-12-22 AP AP2013006984A patent/AP3758A/en active
- 2011-12-22 US US13/334,129 patent/US8921370B2/en not_active Expired - Fee Related
- 2011-12-22 MY MYPI2013002338A patent/MY169432A/en unknown
- 2011-12-22 CN CN201510626898.8A patent/CN105348185B/zh not_active Expired - Fee Related
- 2011-12-22 NZ NZ612000A patent/NZ612000A/en not_active IP Right Cessation
- 2011-12-22 MX MX2015011089A patent/MX349132B/es unknown
- 2011-12-22 MA MA36100A patent/MA34819B1/fr unknown
- 2011-12-22 EP EP11852103.8A patent/EP2654422B1/en active Active
- 2011-12-22 MX MX2013007104A patent/MX2013007104A/es active IP Right Grant
-
2012
- 2012-12-22 PH PH1/2013/501340A patent/PH12013501340A1/en unknown
-
2013
- 2013-06-14 TN TNP2013000253A patent/TN2013000253A1/fr unknown
- 2013-06-16 IL IL226981A patent/IL226981A/en not_active IP Right Cessation
- 2013-06-19 DO DO2013000142A patent/DOP2013000142A/es unknown
- 2013-06-20 GT GT201300164A patent/GT201300164A/es unknown
- 2013-06-21 CR CR20130309A patent/CR20130309A/es unknown
- 2013-06-21 ZA ZA2013/04624A patent/ZA201304624B/en unknown
- 2013-07-17 CO CO13169779A patent/CO6741203A2/es unknown
- 2013-07-23 EC ECSP13012788 patent/ECSP13012788A/es unknown
-
2014
- 2014-08-18 ZA ZA2014/06059A patent/ZA201406059B/en unknown
- 2014-11-04 US US14/532,114 patent/US9656975B2/en not_active Expired - Fee Related
-
2016
- 2016-03-04 JP JP2016041981A patent/JP6087006B2/ja not_active Expired - Fee Related
- 2016-05-17 AU AU2016203192A patent/AU2016203192B2/en not_active Expired - Fee Related
-
2017
- 2017-04-18 US US15/489,971 patent/US20170217950A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014508128A5 (enExample) | ||
| RU2458920C2 (ru) | Новые соединения | |
| KR102093608B1 (ko) | 이미다조피리딘 화합물 | |
| JP2018522823A5 (enExample) | ||
| JP2007514003A5 (enExample) | ||
| RU2009116670A (ru) | Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина | |
| WO2017195216A4 (en) | Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors | |
| JP2017533968A5 (enExample) | ||
| EP3349581A1 (en) | Hepatitis b core protein modulators | |
| JP2017524005A5 (enExample) | ||
| JP2010540462A5 (enExample) | ||
| RU2013130925A (ru) | Оксимовые соединения в качестве средств для повышения уровня холестерина высокой плотности | |
| RU2013108702A (ru) | Ингибиторы деметилазы lsd1 на основе арилциклопропиламина и их применение в медицине | |
| JP2018517746A5 (enExample) | ||
| JP2008513516A5 (enExample) | ||
| RU2017145650A (ru) | Ингибиторы тирозинкиназы брутона | |
| RU2016133626A (ru) | 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера | |
| RU2017116197A (ru) | 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера | |
| JP2011509259A5 (enExample) | ||
| JP2018505898A5 (enExample) | ||
| RU2014145856A (ru) | Азотсодержащее гетероциклическое соединение или его соль | |
| IL264982B (en) | Hetero(aryl)cyclopropylamine compounds as lsd1 inhibitors | |
| JP2013535460A5 (enExample) | ||
| JP2013505903A5 (enExample) | ||
| RU2016134749A (ru) | Гетероциклическое сульфонамидное производное и лекарственное средство, содержащее такое производное |